| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 235 | 2024 | 1945 | 28.780 |
Why?
|
| Heart-Assist Devices | 62 | 2023 | 485 | 13.340 |
Why?
|
| Atrial Fibrillation | 37 | 2022 | 322 | 5.150 |
Why?
|
| Decision Making | 25 | 2023 | 782 | 4.790 |
Why?
|
| Patient Readmission | 27 | 2023 | 610 | 4.470 |
Why?
|
| Stroke Volume | 43 | 2023 | 504 | 4.160 |
Why?
|
| Decision Support Techniques | 16 | 2022 | 355 | 3.850 |
Why?
|
| Ventricular Dysfunction, Left | 15 | 2023 | 358 | 3.330 |
Why?
|
| Registries | 47 | 2023 | 1767 | 3.130 |
Why?
|
| Quality of Life | 42 | 2023 | 2353 | 2.910 |
Why?
|
| Heart Transplantation | 16 | 2023 | 665 | 2.820 |
Why?
|
| Cardiology | 18 | 2022 | 259 | 2.650 |
Why?
|
| Humans | 322 | 2024 | 114654 | 2.640 |
Why?
|
| Patient Participation | 15 | 2023 | 359 | 2.610 |
Why?
|
| Aged | 135 | 2024 | 19068 | 2.330 |
Why?
|
| Palliative Care | 19 | 2023 | 642 | 2.270 |
Why?
|
| Caregivers | 16 | 2023 | 717 | 2.250 |
Why?
|
| Hospice Care | 9 | 2021 | 185 | 2.250 |
Why?
|
| Guideline Adherence | 11 | 2021 | 490 | 2.220 |
Why?
|
| Defibrillators, Implantable | 15 | 2022 | 286 | 2.190 |
Why?
|
| Patient Discharge | 27 | 2023 | 772 | 2.100 |
Why?
|
| Ventricular Function, Left | 17 | 2023 | 467 | 2.010 |
Why?
|
| Hospitalization | 41 | 2023 | 1750 | 2.010 |
Why?
|
| United States | 104 | 2024 | 12179 | 2.000 |
Why?
|
| Practice Patterns, Physicians' | 11 | 2020 | 1177 | 1.940 |
Why?
|
| Medicare | 31 | 2024 | 665 | 1.910 |
Why?
|
| Terminal Care | 9 | 2020 | 213 | 1.880 |
Why?
|
| Male | 155 | 2024 | 55579 | 1.750 |
Why?
|
| Middle Aged | 106 | 2023 | 26732 | 1.750 |
Why?
|
| Female | 160 | 2024 | 59488 | 1.710 |
Why?
|
| Cardiotonic Agents | 10 | 2021 | 119 | 1.700 |
Why?
|
| Risk Assessment | 32 | 2023 | 2968 | 1.680 |
Why?
|
| Outpatients | 10 | 2023 | 326 | 1.670 |
Why?
|
| Aged, 80 and over | 62 | 2023 | 6345 | 1.660 |
Why?
|
| Patient Preference | 6 | 2018 | 167 | 1.620 |
Why?
|
| Ambulatory Care | 7 | 2019 | 478 | 1.590 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 927 | 1.480 |
Why?
|
| Health Status | 14 | 2023 | 722 | 1.480 |
Why?
|
| American Heart Association | 17 | 2023 | 264 | 1.410 |
Why?
|
| Patient-Centered Care | 12 | 2024 | 473 | 1.390 |
Why?
|
| Treatment Outcome | 54 | 2023 | 9087 | 1.390 |
Why?
|
| Anticoagulants | 17 | 2022 | 550 | 1.390 |
Why?
|
| Withholding Treatment | 5 | 2019 | 68 | 1.320 |
Why?
|
| Delivery of Health Care | 11 | 2023 | 833 | 1.310 |
Why?
|
| Prognosis | 29 | 2023 | 3327 | 1.300 |
Why?
|
| Inpatients | 5 | 2023 | 380 | 1.300 |
Why?
|
| Heart Ventricles | 6 | 2021 | 712 | 1.300 |
Why?
|
| Family | 4 | 2023 | 589 | 1.260 |
Why?
|
| Aminobutyrates | 7 | 2023 | 31 | 1.260 |
Why?
|
| Aftercare | 17 | 2023 | 186 | 1.230 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2021 | 1214 | 1.230 |
Why?
|
| Hospitals | 10 | 2024 | 581 | 1.200 |
Why?
|
| Practice Guidelines as Topic | 12 | 2019 | 1394 | 1.190 |
Why?
|
| Health Expenditures | 5 | 2023 | 171 | 1.160 |
Why?
|
| Angiotensin Receptor Antagonists | 10 | 2023 | 76 | 1.160 |
Why?
|
| Stroke | 15 | 2022 | 1021 | 1.160 |
Why?
|
| Cardiovascular Agents | 3 | 2018 | 126 | 1.150 |
Why?
|
| Risk Factors | 46 | 2023 | 8631 | 1.110 |
Why?
|
| Valsartan | 6 | 2022 | 22 | 1.090 |
Why?
|
| Biphenyl Compounds | 7 | 2022 | 50 | 1.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2023 | 179 | 1.090 |
Why?
|
| Patient Care Management | 3 | 2017 | 53 | 1.080 |
Why?
|
| Cardiovascular Diseases | 14 | 2022 | 1727 | 1.060 |
Why?
|
| Surveys and Questionnaires | 21 | 2023 | 4622 | 1.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2021 | 1183 | 1.040 |
Why?
|
| Consumer Health Information | 3 | 2017 | 47 | 1.040 |
Why?
|
| Drug Costs | 4 | 2020 | 92 | 1.020 |
Why?
|
| Adrenergic beta-Antagonists | 7 | 2019 | 287 | 0.980 |
Why?
|
| Heart Failure, Systolic | 3 | 2018 | 20 | 0.970 |
Why?
|
| Patient Selection | 10 | 2019 | 641 | 0.970 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 253 | 0.960 |
Why?
|
| Biomedical Research | 3 | 2020 | 585 | 0.950 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2021 | 160 | 0.940 |
Why?
|
| Internet | 4 | 2020 | 596 | 0.940 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2020 | 106 | 0.920 |
Why?
|
| Quality Improvement | 6 | 2021 | 950 | 0.910 |
Why?
|
| Health Care Costs | 7 | 2023 | 381 | 0.900 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 29 | 0.900 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 680 | 0.900 |
Why?
|
| Survival Analysis | 14 | 2019 | 1211 | 0.880 |
Why?
|
| Cardiovascular System | 5 | 2022 | 125 | 0.880 |
Why?
|
| Quality of Health Care | 8 | 2024 | 573 | 0.870 |
Why?
|
| Follow-Up Studies | 25 | 2023 | 4411 | 0.870 |
Why?
|
| Patient Reported Outcome Measures | 10 | 2023 | 250 | 0.870 |
Why?
|
| Cannabis | 2 | 2022 | 384 | 0.860 |
Why?
|
| Protease Inhibitors | 2 | 2020 | 97 | 0.860 |
Why?
|
| Physicians | 7 | 2023 | 772 | 0.850 |
Why?
|
| Heart Injuries | 1 | 2023 | 37 | 0.830 |
Why?
|
| Clinical Decision-Making | 7 | 2023 | 268 | 0.820 |
Why?
|
| Spirituality | 1 | 2023 | 69 | 0.810 |
Why?
|
| Diuretics | 4 | 2023 | 66 | 0.780 |
Why?
|
| Informed Consent | 3 | 2023 | 161 | 0.760 |
Why?
|
| Catheter Ablation | 4 | 2020 | 288 | 0.750 |
Why?
|
| Device Removal | 2 | 2020 | 126 | 0.750 |
Why?
|
| Insurance, Health | 3 | 2017 | 244 | 0.740 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 444 | 0.740 |
Why?
|
| Transitional Care | 3 | 2021 | 34 | 0.720 |
Why?
|
| Length of Stay | 7 | 2018 | 962 | 0.720 |
Why?
|
| Retrospective Studies | 38 | 2023 | 12544 | 0.710 |
Why?
|
| Health Policy | 3 | 2021 | 334 | 0.700 |
Why?
|
| Medication Adherence | 6 | 2021 | 536 | 0.700 |
Why?
|
| Adult | 48 | 2023 | 30542 | 0.690 |
Why?
|
| Population Health | 1 | 2020 | 42 | 0.670 |
Why?
|
| Attitude to Death | 4 | 2023 | 62 | 0.670 |
Why?
|
| Cardiomyopathies | 3 | 2015 | 298 | 0.660 |
Why?
|
| Biomarkers | 7 | 2023 | 3408 | 0.660 |
Why?
|
| Cause of Death | 8 | 2020 | 361 | 0.660 |
Why?
|
| Telemedicine | 6 | 2024 | 662 | 0.660 |
Why?
|
| Patient Rights | 1 | 2019 | 10 | 0.650 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2018 | 38 | 0.650 |
Why?
|
| Drug Substitution | 2 | 2018 | 46 | 0.640 |
Why?
|
| Propanolamines | 1 | 2019 | 90 | 0.640 |
Why?
|
| Medicaid | 4 | 2021 | 406 | 0.630 |
Why?
|
| Time Factors | 22 | 2023 | 6115 | 0.630 |
Why?
|
| Hemorrhage | 10 | 2022 | 620 | 0.630 |
Why?
|
| Interviews as Topic | 9 | 2021 | 582 | 0.620 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 338 | 0.620 |
Why?
|
| Quality Assurance, Health Care | 3 | 2015 | 311 | 0.610 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 330 | 0.610 |
Why?
|
| Patient Care Team | 4 | 2018 | 517 | 0.600 |
Why?
|
| Hospices | 5 | 2021 | 83 | 0.600 |
Why?
|
| Health Status Indicators | 3 | 2020 | 156 | 0.600 |
Why?
|
| Manuscripts, Medical as Topic | 1 | 2017 | 4 | 0.600 |
Why?
|
| Warfarin | 7 | 2022 | 135 | 0.590 |
Why?
|
| Heart Diseases | 2 | 2014 | 331 | 0.590 |
Why?
|
| Attitude to Health | 4 | 2019 | 406 | 0.580 |
Why?
|
| Peer Review | 1 | 2017 | 43 | 0.580 |
Why?
|
| Peer Review, Research | 1 | 2017 | 34 | 0.580 |
Why?
|
| Physician-Patient Relations | 3 | 2020 | 462 | 0.580 |
Why?
|
| Cocaine | 1 | 2019 | 153 | 0.570 |
Why?
|
| Stress, Psychological | 3 | 2021 | 944 | 0.570 |
Why?
|
| Editorial Policies | 1 | 2017 | 45 | 0.560 |
Why?
|
| Disease Progression | 14 | 2019 | 2380 | 0.560 |
Why?
|
| Insurance Claim Review | 2 | 2014 | 67 | 0.550 |
Why?
|
| Advance Care Planning | 2 | 2019 | 197 | 0.550 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 174 | 0.550 |
Why?
|
| Prospective Studies | 20 | 2022 | 6217 | 0.550 |
Why?
|
| Angina, Unstable | 3 | 2006 | 72 | 0.540 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 132 | 0.530 |
Why?
|
| Quality Indicators, Health Care | 7 | 2021 | 287 | 0.530 |
Why?
|
| Societies, Medical | 5 | 2019 | 663 | 0.520 |
Why?
|
| Comorbidity | 13 | 2023 | 1448 | 0.520 |
Why?
|
| Disease Management | 6 | 2022 | 560 | 0.520 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 931 | 0.520 |
Why?
|
| Survival Rate | 10 | 2020 | 1644 | 0.510 |
Why?
|
| Aortic Valve Stenosis | 2 | 2021 | 272 | 0.500 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 72 | 0.500 |
Why?
|
| Digoxin | 1 | 2015 | 26 | 0.500 |
Why?
|
| Healthcare Disparities | 7 | 2023 | 480 | 0.500 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 181 | 0.500 |
Why?
|
| Heart Rate | 4 | 2020 | 709 | 0.490 |
Why?
|
| Cohort Studies | 16 | 2023 | 4895 | 0.490 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2022 | 94 | 0.490 |
Why?
|
| Multimedia | 1 | 2014 | 10 | 0.480 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 349 | 0.480 |
Why?
|
| Frail Elderly | 2 | 2013 | 106 | 0.470 |
Why?
|
| Health Personnel | 2 | 2022 | 574 | 0.470 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 239 | 0.470 |
Why?
|
| Proportional Hazards Models | 13 | 2019 | 1075 | 0.470 |
Why?
|
| Colorado | 12 | 2021 | 4099 | 0.460 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 2537 | 0.460 |
Why?
|
| Population Surveillance | 1 | 2017 | 392 | 0.460 |
Why?
|
| Skilled Nursing Facilities | 2 | 2016 | 121 | 0.450 |
Why?
|
| Socioeconomic Factors | 6 | 2022 | 1078 | 0.450 |
Why?
|
| Fluid Therapy | 1 | 2015 | 123 | 0.450 |
Why?
|
| Acute Disease | 7 | 2023 | 910 | 0.450 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 212 | 0.450 |
Why?
|
| Hip Prosthesis | 1 | 2014 | 33 | 0.450 |
Why?
|
| Hospital Mortality | 8 | 2023 | 776 | 0.440 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 53 | 0.440 |
Why?
|
| Hyperkalemia | 1 | 2013 | 26 | 0.440 |
Why?
|
| Hand Strength | 1 | 2014 | 95 | 0.430 |
Why?
|
| Tetrazoles | 6 | 2023 | 32 | 0.430 |
Why?
|
| Preoperative Period | 1 | 2013 | 103 | 0.430 |
Why?
|
| Life Expectancy | 2 | 2016 | 51 | 0.430 |
Why?
|
| Electrocardiography | 5 | 2023 | 560 | 0.420 |
Why?
|
| Prosthesis Failure | 1 | 2014 | 115 | 0.420 |
Why?
|
| Algorithms | 4 | 2022 | 1467 | 0.420 |
Why?
|
| Models, Statistical | 2 | 2014 | 599 | 0.420 |
Why?
|
| Drug Combinations | 7 | 2022 | 287 | 0.420 |
Why?
|
| Patient Admission | 3 | 2015 | 176 | 0.410 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2022 | 279 | 0.410 |
Why?
|
| Coronary Artery Bypass | 2 | 2011 | 196 | 0.410 |
Why?
|
| Furosemide | 2 | 2023 | 32 | 0.410 |
Why?
|
| Neprilysin | 3 | 2023 | 47 | 0.400 |
Why?
|
| Cardiac Catheterization | 3 | 2020 | 534 | 0.400 |
Why?
|
| Chronic Disease | 10 | 2022 | 1578 | 0.390 |
Why?
|
| Qualitative Research | 8 | 2020 | 934 | 0.390 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 130 | 0.390 |
Why?
|
| Aortic Valve | 2 | 2021 | 398 | 0.380 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 410 | 0.380 |
Why?
|
| Emotions | 7 | 2023 | 472 | 0.380 |
Why?
|
| Social Environment | 1 | 2013 | 283 | 0.380 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 4407 | 0.370 |
Why?
|
| Adaptation, Psychological | 7 | 2023 | 547 | 0.370 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2020 | 195 | 0.370 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2023 | 176 | 0.360 |
Why?
|
| Age Factors | 12 | 2020 | 2894 | 0.360 |
Why?
|
| Myocarditis | 2 | 2022 | 93 | 0.360 |
Why?
|
| Health Literacy | 4 | 2022 | 164 | 0.360 |
Why?
|
| Income | 3 | 2020 | 167 | 0.360 |
Why?
|
| Research Report | 5 | 2022 | 75 | 0.350 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2017 | 99 | 0.350 |
Why?
|
| Risk | 4 | 2019 | 812 | 0.350 |
Why?
|
| Communication | 5 | 2023 | 744 | 0.350 |
Why?
|
| Erythrocyte Indices | 1 | 2009 | 27 | 0.340 |
Why?
|
| Poverty | 1 | 2013 | 442 | 0.330 |
Why?
|
| Cardiologists | 3 | 2018 | 40 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2021 | 486 | 0.330 |
Why?
|
| Sex Factors | 7 | 2021 | 1715 | 0.330 |
Why?
|
| Consensus | 6 | 2022 | 537 | 0.330 |
Why?
|
| Hemodynamics | 5 | 2023 | 1012 | 0.320 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 228 | 0.320 |
Why?
|
| Weights and Measures | 1 | 2008 | 7 | 0.310 |
Why?
|
| Eligibility Determination | 2 | 2021 | 60 | 0.310 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 138 | 0.310 |
Why?
|
| Liver Function Tests | 1 | 2009 | 103 | 0.310 |
Why?
|
| Pain | 2 | 2018 | 705 | 0.310 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 248 | 0.310 |
Why?
|
| Anemia | 1 | 2009 | 143 | 0.310 |
Why?
|
| Research Design | 5 | 2023 | 928 | 0.300 |
Why?
|
| Administration, Oral | 9 | 2021 | 728 | 0.300 |
Why?
|
| Internationality | 1 | 2008 | 143 | 0.290 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2008 | 63 | 0.290 |
Why?
|
| Multivariate Analysis | 7 | 2013 | 1430 | 0.290 |
Why?
|
| Erythrocytes | 2 | 2009 | 591 | 0.290 |
Why?
|
| Incidence | 10 | 2018 | 2312 | 0.290 |
Why?
|
| Mitral Valve | 1 | 2008 | 86 | 0.290 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2022 | 42 | 0.280 |
Why?
|
| Betacoronavirus | 2 | 2020 | 250 | 0.280 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 637 | 0.280 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1862 | 0.280 |
Why?
|
| Referral and Consultation | 5 | 2023 | 632 | 0.280 |
Why?
|
| Models, Cardiovascular | 1 | 2008 | 178 | 0.280 |
Why?
|
| Hospitals, Community | 2 | 2020 | 45 | 0.280 |
Why?
|
| Prosthesis Design | 4 | 2018 | 285 | 0.270 |
Why?
|
| Patient Care | 2 | 2023 | 101 | 0.270 |
Why?
|
| Choice Behavior | 2 | 2020 | 155 | 0.270 |
Why?
|
| Pilot Projects | 6 | 2022 | 1373 | 0.260 |
Why?
|
| Patient Satisfaction | 4 | 2020 | 578 | 0.260 |
Why?
|
| Evidence-Based Medicine | 4 | 2021 | 668 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 544 | 0.260 |
Why?
|
| Frailty | 2 | 2019 | 115 | 0.260 |
Why?
|
| Cost of Illness | 5 | 2020 | 254 | 0.260 |
Why?
|
| Mass Screening | 2 | 2010 | 1004 | 0.250 |
Why?
|
| Prosthesis Implantation | 2 | 2019 | 138 | 0.250 |
Why?
|
| Prevalence | 9 | 2020 | 2250 | 0.250 |
Why?
|
| Patient Compliance | 4 | 2019 | 525 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2020 | 681 | 0.250 |
Why?
|
| Marijuana Smoking | 2 | 2020 | 224 | 0.240 |
Why?
|
| Mortality | 4 | 2020 | 287 | 0.240 |
Why?
|
| Electric Countershock | 3 | 2020 | 104 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 811 | 0.240 |
Why?
|
| Neoplasms | 3 | 2023 | 2097 | 0.240 |
Why?
|
| Depression | 4 | 2020 | 1134 | 0.230 |
Why?
|
| Digital Divide | 1 | 2024 | 3 | 0.230 |
Why?
|
| Mobile Applications | 2 | 2024 | 141 | 0.230 |
Why?
|
| Creatinine | 3 | 2023 | 425 | 0.230 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 371 | 0.220 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 2762 | 0.220 |
Why?
|
| Congresses as Topic | 3 | 2021 | 195 | 0.220 |
Why?
|
| Clinical Coding | 2 | 2014 | 19 | 0.220 |
Why?
|
| Chest Pain | 1 | 2023 | 81 | 0.220 |
Why?
|
| Probability | 3 | 2016 | 289 | 0.220 |
Why?
|
| Urea | 1 | 2023 | 67 | 0.220 |
Why?
|
| Perinatal Care | 1 | 2023 | 36 | 0.210 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 3 | 0.210 |
Why?
|
| Hydralazine | 1 | 2023 | 5 | 0.210 |
Why?
|
| Troponin | 1 | 2023 | 44 | 0.210 |
Why?
|
| Denmark | 1 | 2023 | 39 | 0.210 |
Why?
|
| Cardiac Rehabilitation | 1 | 2023 | 32 | 0.210 |
Why?
|
| Drug Utilization | 2 | 2015 | 167 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 2094 | 0.210 |
Why?
|
| Recovery of Function | 4 | 2020 | 574 | 0.210 |
Why?
|
| Death | 1 | 2023 | 107 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2008 | 1015 | 0.200 |
Why?
|
| Atrial Appendage | 1 | 2022 | 10 | 0.200 |
Why?
|
| Pandemics | 2 | 2020 | 1317 | 0.200 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 17 | 0.200 |
Why?
|
| Cognition | 4 | 2021 | 989 | 0.190 |
Why?
|
| Anxiety | 3 | 2018 | 840 | 0.190 |
Why?
|
| Advisory Committees | 2 | 2021 | 208 | 0.190 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2021 | 70 | 0.190 |
Why?
|
| Hypertension | 3 | 2021 | 1056 | 0.190 |
Why?
|
| Universities | 1 | 2023 | 340 | 0.190 |
Why?
|
| Trust | 1 | 2022 | 105 | 0.190 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 88 | 0.180 |
Why?
|
| Age Distribution | 3 | 2012 | 342 | 0.180 |
Why?
|
| Myocardial Contraction | 2 | 2019 | 313 | 0.180 |
Why?
|
| Relaxin | 1 | 2020 | 15 | 0.180 |
Why?
|
| Georgia | 1 | 2020 | 62 | 0.180 |
Why?
|
| Norway | 1 | 2020 | 36 | 0.180 |
Why?
|
| Health Systems Plans | 1 | 2020 | 3 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2020 | 401 | 0.180 |
Why?
|
| Financing, Government | 1 | 2020 | 40 | 0.180 |
Why?
|
| Psychology | 1 | 2021 | 82 | 0.180 |
Why?
|
| Home Care Services | 2 | 2020 | 222 | 0.180 |
Why?
|
| Palliative Medicine | 2 | 2018 | 14 | 0.180 |
Why?
|
| Pyridones | 1 | 2021 | 123 | 0.170 |
Why?
|
| Health Services Misuse | 1 | 2020 | 36 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 106 | 0.170 |
Why?
|
| Diagnosis-Related Groups | 2 | 2021 | 26 | 0.170 |
Why?
|
| Health Resources | 2 | 2012 | 122 | 0.170 |
Why?
|
| Odds Ratio | 5 | 2014 | 953 | 0.170 |
Why?
|
| Thoracentesis | 1 | 2019 | 8 | 0.170 |
Why?
|
| Nurses | 3 | 2018 | 145 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 126 | 0.170 |
Why?
|
| Mandatory Programs | 1 | 2019 | 15 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 165 | 0.170 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2019 | 10 | 0.160 |
Why?
|
| Dyspnea | 3 | 2018 | 211 | 0.160 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 241 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 249 | 0.160 |
Why?
|
| Fatigue | 3 | 2018 | 294 | 0.160 |
Why?
|
| Mental Competency | 1 | 2019 | 26 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2022 | 341 | 0.160 |
Why?
|
| Coronary Artery Disease | 3 | 2019 | 607 | 0.160 |
Why?
|
| Text Messaging | 1 | 2021 | 152 | 0.160 |
Why?
|
| Home Infusion Therapy | 1 | 2018 | 4 | 0.160 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 243 | 0.160 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 135 | 0.160 |
Why?
|
| Fee-for-Service Plans | 2 | 2018 | 83 | 0.160 |
Why?
|
| Medical Marijuana | 1 | 2020 | 97 | 0.160 |
Why?
|
| Contraindications | 2 | 2015 | 85 | 0.150 |
Why?
|
| Thromboembolism | 2 | 2021 | 92 | 0.150 |
Why?
|
| Patient Safety | 3 | 2021 | 277 | 0.150 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 975 | 0.150 |
Why?
|
| Ventricular Function | 1 | 2018 | 57 | 0.150 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 20 | 0.150 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 77 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 718 | 0.150 |
Why?
|
| Cost Savings | 2 | 2021 | 74 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1842 | 0.150 |
Why?
|
| Heart Conduction System | 1 | 2018 | 80 | 0.150 |
Why?
|
| Spouses | 1 | 2018 | 85 | 0.150 |
Why?
|
| Mental Health | 1 | 2023 | 562 | 0.150 |
Why?
|
| Thrombosis | 1 | 2021 | 298 | 0.140 |
Why?
|
| Medical Records | 1 | 2018 | 153 | 0.140 |
Why?
|
| Quality Control | 1 | 2017 | 144 | 0.140 |
Why?
|
| Spiritual Therapies | 1 | 2017 | 9 | 0.140 |
Why?
|
| Vaccines | 1 | 2022 | 375 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 253 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2018 | 218 | 0.140 |
Why?
|
| Caliciviridae Infections | 1 | 2016 | 17 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 951 | 0.140 |
Why?
|
| Pain Management | 2 | 2016 | 288 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2012 | 1125 | 0.130 |
Why?
|
| Mexiletine | 1 | 2016 | 7 | 0.130 |
Why?
|
| Amphetamine | 1 | 2016 | 22 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1796 | 0.130 |
Why?
|
| Defibrillators | 1 | 2016 | 16 | 0.130 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 117 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2016 | 39 | 0.130 |
Why?
|
| Public Health | 1 | 2020 | 433 | 0.130 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1815 | 0.130 |
Why?
|
| Bereavement | 1 | 2016 | 49 | 0.130 |
Why?
|
| Substance Abuse Detection | 1 | 2016 | 62 | 0.130 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 429 | 0.130 |
Why?
|
| Uncertainty | 1 | 2016 | 95 | 0.130 |
Why?
|
| Psychotherapy | 1 | 2017 | 149 | 0.130 |
Why?
|
| Social Security | 1 | 2015 | 4 | 0.130 |
Why?
|
| Medical Indigency | 1 | 2015 | 11 | 0.130 |
Why?
|
| Kidney | 2 | 2020 | 1188 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2017 | 211 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2016 | 140 | 0.120 |
Why?
|
| Young Adult | 7 | 2019 | 10465 | 0.120 |
Why?
|
| Self Care | 2 | 2019 | 349 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 184 | 0.120 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 35 | 0.120 |
Why?
|
| Polypharmacy | 1 | 2015 | 74 | 0.120 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2014 | 22 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 284 | 0.120 |
Why?
|
| Assisted Circulation | 1 | 2014 | 25 | 0.120 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 51 | 0.120 |
Why?
|
| Health Surveys | 3 | 2023 | 443 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 83 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 122 | 0.110 |
Why?
|
| Critical Care | 1 | 2018 | 476 | 0.110 |
Why?
|
| Cobalt | 1 | 2014 | 46 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 381 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1108 | 0.110 |
Why?
|
| Potassium | 1 | 2013 | 128 | 0.110 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 380 | 0.110 |
Why?
|
| Women's Health | 1 | 2015 | 271 | 0.110 |
Why?
|
| Data Collection | 1 | 2016 | 620 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2023 | 5044 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1879 | 0.100 |
Why?
|
| Anthracyclines | 1 | 2012 | 41 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 176 | 0.100 |
Why?
|
| Health Maintenance Organizations | 1 | 2012 | 93 | 0.100 |
Why?
|
| Drug Utilization Review | 1 | 2012 | 57 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2019 | 1958 | 0.100 |
Why?
|
| Patients | 2 | 2024 | 163 | 0.100 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 50 | 0.100 |
Why?
|
| Pregnancy | 1 | 2023 | 5517 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 249 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 900 | 0.100 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2012 | 48 | 0.100 |
Why?
|
| Acculturation | 1 | 2012 | 50 | 0.100 |
Why?
|
| Tachycardia | 1 | 2011 | 50 | 0.090 |
Why?
|
| Echocardiography | 1 | 2014 | 553 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 235 | 0.090 |
Why?
|
| Hyponatremia | 1 | 2011 | 37 | 0.090 |
Why?
|
| Culture | 1 | 2012 | 124 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2017 | 701 | 0.090 |
Why?
|
| Motivation | 1 | 2015 | 494 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2015 | 476 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 604 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 913 | 0.090 |
Why?
|
| Logistic Models | 2 | 2013 | 1840 | 0.090 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2010 | 8 | 0.090 |
Why?
|
| Health Services Research | 1 | 2013 | 371 | 0.090 |
Why?
|
| Minority Groups | 1 | 2012 | 227 | 0.090 |
Why?
|
| Erythropoiesis | 1 | 2009 | 33 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2020 | 305 | 0.090 |
Why?
|
| Benzazepines | 1 | 2010 | 37 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 198 | 0.080 |
Why?
|
| Focus Groups | 2 | 2023 | 383 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1342 | 0.080 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 56 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 373 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2009 | 68 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2011 | 275 | 0.080 |
Why?
|
| ROC Curve | 1 | 2010 | 442 | 0.080 |
Why?
|
| Bilirubin | 1 | 2009 | 88 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 86 | 0.080 |
Why?
|
| Alberta | 1 | 2008 | 10 | 0.080 |
Why?
|
| Actuarial Analysis | 1 | 2008 | 21 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 321 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2177 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 172 | 0.080 |
Why?
|
| Syndrome | 1 | 2009 | 333 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 141 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 143 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2009 | 137 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 663 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 947 | 0.070 |
Why?
|
| Social Support | 3 | 2019 | 528 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 1352 | 0.070 |
Why?
|
| Insurance Coverage | 2 | 2021 | 200 | 0.070 |
Why?
|
| Child | 2 | 2023 | 18407 | 0.070 |
Why?
|
| Social Workers | 2 | 2018 | 32 | 0.070 |
Why?
|
| Ultrafiltration | 1 | 2007 | 27 | 0.070 |
Why?
|
| Heart Function Tests | 1 | 2007 | 58 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2007 | 138 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2009 | 255 | 0.070 |
Why?
|
| Lung | 1 | 2018 | 3559 | 0.060 |
Why?
|
| Genomics | 1 | 2010 | 635 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2020 | 740 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 762 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 302 | 0.060 |
Why?
|
| Proteomics | 1 | 2010 | 836 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2006 | 211 | 0.060 |
Why?
|
| Natriuretic Peptides | 1 | 2023 | 8 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1121 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 414 | 0.060 |
Why?
|
| Critical Illness | 1 | 2008 | 644 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 60 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2023 | 143 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 72 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3044 | 0.050 |
Why?
|
| Heuristics | 1 | 2022 | 8 | 0.050 |
Why?
|
| Information Systems | 1 | 2023 | 61 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 11 | 0.050 |
Why?
|
| Sexism | 1 | 2023 | 44 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 33 | 0.050 |
Why?
|
| Massachusetts | 1 | 2022 | 134 | 0.050 |
Why?
|
| Phenotype | 2 | 2021 | 2796 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 144 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 183 | 0.050 |
Why?
|
| Program Development | 1 | 2023 | 341 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 80 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2022 | 75 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 137 | 0.050 |
Why?
|
| Exercise Test | 1 | 2023 | 544 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 299 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 229 | 0.040 |
Why?
|
| Urban Health Services | 1 | 2020 | 60 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 116 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 17 | 0.040 |
Why?
|
| Private Sector | 1 | 2020 | 51 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2020 | 92 | 0.040 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 29 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 73 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 59 | 0.040 |
Why?
|
| Embolism | 1 | 2019 | 43 | 0.040 |
Why?
|
| Contraindications, Procedure | 1 | 2019 | 11 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 322 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 31 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2019 | 67 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 121 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 97 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2023 | 640 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 90 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 120 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 101 | 0.040 |
Why?
|
| Government Regulation | 1 | 2018 | 46 | 0.040 |
Why?
|
| Survival | 1 | 2018 | 37 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1691 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 331 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 52 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2018 | 31 | 0.040 |
Why?
|
| Patient Health Questionnaire | 1 | 2018 | 21 | 0.040 |
Why?
|
| Policy Making | 1 | 2018 | 81 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 666 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 21 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 213 | 0.040 |
Why?
|
| Medicare Part D | 1 | 2018 | 26 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 127 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2387 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 201 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 335 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1230 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 258 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 896 | 0.040 |
Why?
|
| Risk Management | 1 | 2018 | 89 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 615 | 0.030 |
Why?
|
| Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
|
| Atropine | 1 | 2016 | 25 | 0.030 |
Why?
|
| Loperamide | 1 | 2016 | 10 | 0.030 |
Why?
|
| Antidiarrheals | 1 | 2016 | 15 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 224 | 0.030 |
Why?
|
| Emotional Adjustment | 1 | 2016 | 17 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 36 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 921 | 0.030 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 5 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2016 | 27 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 455 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 60 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 289 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 121 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2016 | 48 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2016 | 119 | 0.030 |
Why?
|
| Video Recording | 1 | 2016 | 143 | 0.030 |
Why?
|
| Life Change Events | 1 | 2016 | 135 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 222 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2014 | 26 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 139 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 743 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 768 | 0.030 |
Why?
|
| Family Relations | 1 | 2015 | 85 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2015 | 85 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2018 | 617 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 993 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 280 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 372 | 0.030 |
Why?
|
| Proteinuria | 1 | 2013 | 77 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2014 | 244 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 511 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 646 | 0.030 |
Why?
|
| Systole | 1 | 2013 | 171 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2012 | 89 | 0.030 |
Why?
|
| Global Health | 1 | 2014 | 287 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 493 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 109 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2015 | 337 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 1012 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 330 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 185 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2012 | 159 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 332 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2012 | 264 | 0.020 |
Why?
|
| Medical Audit | 1 | 2011 | 75 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2011 | 133 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 314 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 204 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 1728 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2008 | 45 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 63 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2285 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2085 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1355 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 3345 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 17837 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 31698 | 0.010 |
Why?
|